11. Clinical benefit table: Durolane. Continuous outcome measures.

Study	Time	Treatment	Outcome	N of Pts	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference
Altman 2004	1‐4 wk	E: Durolane	WOMAC pain (0‐20)	172	9.90	6.75	0.24 (W)	2.3% (W)
		C: Saline		174	10.42	7.03
Altman 2004	1‐4 wk	E: Durolane	WOMAC function (0‐68)	172	30.70	23.18	1.00 (W)	3.1% (W)
		C: Saline		174	32.16	23.64
Altman 2004	1‐4 wk	E: Durolane	WOMAC stiffness (0‐8)	172	3.91	3.04	0.16 (W)	3.7% (W)
		C: Saline		174	4.30	3.27
Altman 2004	5‐13 wk	E: Durolane	WOMAC pain (0‐20)	172	9.90	7.03	0.55 (W)	5.3% (W)
		C: Saline		174	10.42	7.00
Altman 2004	5‐13 wk	E: Durolane	WOMAC function (0‐68)	172	30.70	23.72	1.74 (W)	5.4% (W)
		C: Saline		174	32.16	23.44
Altman 2004	5‐13 wk	E: Durolane	WOMAC stiffness (0‐8)	172	3.91	3.20	0.34 (W)	7.9% (W)
		C: Saline		174	4.30	3.25
Altman 2004	14‐26 wk	E: Durolane	WOMAC pain (0‐20)	172	9.90	7.40	0.39 (W)	3.7% (W)
		C: Saline		174	10.42	7.53
Altman 2004	14‐26 wk	E: Durolane	WOMAC function (0‐68)	172	30.70	24.88	1.60 (W)	5.0% (W)
		C: Saline		174	32.16	24.74
Altman 2004	14‐26 wk	E: Durolane	WOMAC stiffness (0‐8)	172	3.91	3.44	0.35 (W)	8.1% (W)
		C: Saline		174	4.30	3.48